New hope for lung cancer patients: experimental drug YL202 faces off against chemotherapy
NCT ID NCT07416994
First seen Feb 18, 2026 · Last updated May 12, 2026 · Updated 8 times
Summary
This study compares a new drug called YL202 to the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific EGFR mutation. Participants must have already tried an EGFR-targeted pill and platinum chemotherapy without success. The goal is to see if YL202 helps people live longer or keeps the cancer from growing longer than docetaxel.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Dongfang Hospital
Shanghai, Shanghai Municipality, 200120, China
Contact
-
Zhejiang Provincial Cancer
Hangzhou, Zhejiang, 310022, China
Contact
Conditions
Explore the condition pages connected to this study.